en · de · es · pt
hplc-notes.peptides6823.com › Guide › Bpc-157 Identity And Origin — Reference Sheet

Bpc-157 Identity And Origin — Reference Sheet

By Editorial Desk · published 2026-04-01 · last reviewed 2026-04-20 · Guide

Everything below concerns Reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

BPC-157 Identity and Origin

BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.

Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.

Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.

Storage, Handling, and Analytical Verification

Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.

Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.

Bpc-157 at a glance

PropertyValueNotes
ClassSynthetic peptideLinear, fifteen residues
SequenceGEPPPGKPADDAGLVSingle-letter amino acid code
Approximate mass1419 DaValue reported for the free peptide
Reported originFragment of a gastric juice proteinUsed as the design template
Common synonymsBody protection compound 157; PL 14736Naming varies across papers and suppliers

BPC-157 Handling and Analysis

Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.

BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.

Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.

Related pages on this site

Analysis, Stability, and Handling

Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.

Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.

Discovery and Research Background

BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.

Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.

Notes from published material

Acute cutaneous lupus erythematosus Atrophoderma of Pasini and Pierini (dyschromic and atrophic variation of scleroderma, morphea plana atrophica, sclérodermie atrophique d'emblée) Calcinosis–Raynaud phenomenon–esophageal dysmotility–sclerodactyly–telangiectasia syndrome (CREST syndrome) Chilblain lupus erythematosus (chilblain lupus erythematosus of Hutchinson) Childhood dermatomyositis Childhood discoid lupus erythematosus Childhood systemic lupus erythematosus Complement deficiency syndromes Dermatomyositis Ehlers–Danlos syndrome Eosinophilia–myalgia syndrome Frontal linear scleroderma (en coup de sabre, morphea en coup de sabre) Generalized discoid lupus erythematosus Generalized morphea Interstitial granulomatous dermatitis Juvenile rheumatoid arthritis (juvenile idiopathic arthritis, Still's disease) Keloid morphea Linear atrophoderma of Moulin (Moulin atrophoderma linearis) Linear scleroderma Localized discoid lupus erythematosus Localized morphea Lupus erythematosus panniculitis (lupus erythematosus profundus, lupus panniculitis, lupus profundus, subcutaneous lupus erythematosus) Lupus erythematosus–lichen planus overlap syndrome (lichen planus–lupus erythematosus overlap syndrome) Methotrexate-induced papular eruption Mixed connective tissue disease (Sharp's syndrome, undifferentiated connective tissue disease) Morphea profunda Morphea–lichen sclerosus et atrophicus overlap Mouth and genital ulcers with inflamed cartilage syndrome (MAGIC syndrome) Neonatal lupus erythematosus Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) Nicolau–Balus syndrome Nodulosis–arthropathy–osteolysis syndrome Normophosphatemic familial tumoral calcinosis Palisaded neutrophilic and granulomatous dermatitis Pansclerotic morphea Parry–Romberg syndrome (progressive hemifacial atrophy) Progressive systemic sclerosis Relapsing polychondritis (atrophic polychondritis, systemic chondromalacia) Rheumatoid arthritis Rheumatoid nodulosis (accelerated rheumatoid nodulosis) Rheumatoid vasculitis Rowell's syndrome Scleredema adultorum (Bushke disease, scleredema diabeticorum, scleredema adultorum of Buschke, scleredema of Buschke) Silicosis Sjögren's syndrome (Mikulicz disease, Sicca syndrome) Subacute cutaneous lupus erythematosus Systemic lupus erythematosus Toxic oil syndrome Tumid lupus erythematosus (lupus erythematosus tumidus) Tuzun syndrome Verrucous lupus erythematosus (hypertrophic lupus erythematosus) Winchester syndrome

==== 2001–2006: Second double, Invincibles, and leaving Highbury ==== The cup defeat prompted Wenger to make changes to his squad. He signed young England internationals Richard Wright and Francis Jeffers, midfielder Giovanni van Bronckhorst from Rangers as a partner for Vieira, and convinced defender Sol Campbell to join from local rivals Tottenham Hotspur on a free transfer. Campbell's arrival strengthened a defence which was going through a transition phase from 1999 and 2001; Steve Bould and Nigel Winterburn moved on in this period, club graduate Ashley Cole displaced Sylvinho as Wenger's first choice left back, while Lauren acted as Lee Dixon's understudy. Midfielders Freddie Ljungberg and Robert Pires – brought in during preceding transfer windows, had now established themselves into the first team. The 2001–02 season brought much success as Wenger led Arsenal to the double once more. The crowning moment was the win against Manchester United at Old Trafford in the penultimate game of the season. Sylvain Wiltord scored the winning goal to secure the club's 12th league championship and third double; four days earlier, Arsenal beat Chelsea 2–0 in the 2002 FA Cup Final. The team scored in every single league fixture and were unbeaten away from home that season.

Kipa-Williams commented "Ari initially believes Tane robbed the Diner. But he also believes Colby is acting out of jealousy more than anything else." Ari and Tane realise they need to put some distance between themselves and the Bay when Nikau discovers Colby is planning on conducting a police line-up involving them all. Nikau later steals Tori's car in order to flee the Bay, but he accidentally kidnaps her young daughter Grace. Tane helps him return Grace to Tori anonymously, but Colby realises that the Paratas were involved in the car-jacking. Sarah Ellis of Inside Soap observed that with "the heat on their family", the brothers know they need to act fast. When they learn Gemma is planning a trip to New Zealand to scatter the ashes of her husband, they seize the chance to escape. A show spokesperson told Ellis: "It's not just about evading the law, Ari and Tane both want to pay their respects to their late brother Mikaere. So the family presses ahead with their plans, hoping that getting to New Zealand will give them time to consider their options. But things don't turn out how they'd planned..." When Colby hears the Paratas are leaving the country, he puts a block on their passports, so only Gemma is able to pass through security at the airport, while the men are detained. The storyline marked Gemma's departure from the serial. Despite a possible jail sentence hanging over them, the Parata men are keen to honour their late brother and father, so they go to the beach and perform a "deeply spiritual and moving" Haka ceremony to say their goodbyes to Mikaere.

The large intestine forms an arch starting at the cecum and ending at the rectum and anal canal. It also includes the appendix, which is attached to the cecum. Its length is about 1.5 m, and the area of the mucosa in an adult human is about 2 m2 (22 sq ft). The longest part of the large intestine is the colon whose main function is to absorb water and salts. The large intestine begins at the cecum, where the appendix is located. This is also the start of the colon as the ascending colon in the back wall of the abdomen. At the right colic flexure (hepatic flexure) (the flexed portion of the ascending and transverse colon) it runs across the abdomen in the transverse colon, passing below the diaphragm. At the left colic flexure (splenic flexure) the flexed portion of the transverse and descending colon, it descends down the left side of the abdomen. It reaches the sigmoid colon which is a loop of the colon closest to the rectum and continues to the rectum and anal canal.

Sources: en.wikipedia.org

Background from the literature

== Early life == Princess Zita of Bourbon-Parma was born at the Villa Pianore in the Italian Province of Lucca, 9 May 1892. The unusual name Zita was given to her after Zita, a popular Italian saint who had lived in Tuscany in the 13th century. She was the third daughter and fifth child of the deposed Robert I, Duke of Parma, and his second wife, Infanta Maria Antonia of Portugal, a daughter of King Miguel of Portugal and his wife Adelaide of Löwenstein-Wertheim-Rosenberg. Zita's father had lost his throne as a result of the movement for Italian unification in 1859 when he was still a child. He fathered twelve children during his first marriage to Princess Maria Pia of the Two Sicilies (six of whom were mentally disabled, and three of whom died young). Duke Robert became a widower in 1882, and two years later he married Infanta Maria Antonia of Portugal. The second marriage produced a further twelve children. Zita was the 17th among Duke Robert's 24 children. Robert moved his large family between Villa Pianore (a large property located between Pietrasanta and Viareggio) and his Schwarzau Castle in Lower Austria. It was mainly in these two residences that Zita spent her formative years. The family spent most of the year in Austria, moving to Pianore in the winter and returning in the summer. To move between them, they took a special train with sixteen coaches to accommodate the family and their belongings.

=== Overnutrition === Excessive consumption of energy-dense foods and drinks and limited physical activity causes overnutrition. It causes overweight, defined as a body mass index (BMI) of 25 or more, and can lead to obesity (a BMI of 30 or more). Obesity has become a major health issue worldwide. Overnutrition is linked to chronic non-communicable diseases like diabetes, certain cancers, and cardiovascular diseases. Hence identifying and addressing the immediate risk factors has become a major health priority. The recent evidence on the impact of diet-induced obesity in fathers and mothers around the time of conception is identified to negatively program the health outcomes of multiple generations. According to UNICEF, at least 1 in every 10 children under five is overweight in 33 countries.

One of the claimants of the English throne opposing William the Conqueror, Edgar Atheling, eventually fled to Scotland. King Malcolm III of Scotland married Edgar's sister Margaret, and came into opposition to William who had already disputed Scotland's southern borders. William invaded Scotland in 1072, riding as far as Abernethy where he met up with his fleet of ships. Malcolm submitted, paid homage to William and surrendered his son Duncan as a hostage, beginning a series of arguments as to whether the Scottish Crown owed allegiance to the King of England. Normans went into Scotland, building castles and founding noble families that would provide some future kings, such as Robert the Bruce, as well as founding a considerable number of the Scottish clans. King David I of Scotland, whose elder brother Alexander I had married Sybilla of Normandy, was instrumental in introducing Normans and Norman culture to Scotland, part of the process some scholars call the "Davidian Revolution". Having spent time at the court of Henry I of England (married to David's sister Maud of Scotland), and needing them to wrestle the kingdom from his nephew Máel Coluim mac Alaxandair, David had to reward many with lands. The process was continued under David's successors, most intensely of all under William the Lion. The Norman-derived feudal system was applied in varying degrees to most of Scotland.

Structural and computational studies have revealed that the metal binds the two carbonyl oxygens of the methylglyoxal moiety at two of its coordination sites, stabilizing the enediolate anion intermediate. Another unusual property of glyoxalase I is its inconsistent stereospecificity. The first step of its reaction mechanism (the abstraction of the proton from C1 and subsequent protonation of O2) is not stereospecific and works equally well regardless of the initial chirality at C1 in the hemithioacetal substrate. The resulting enediolate intermediate is achiral, but the second step of the reaction mechanism (the abstraction of a proton from O1 and subsequent protonation of C2) is definitely stereospecific, producing only the (S) form of D-lactoylglutathione. This is believed to result from the two glutamates bound oppositely on the metal ion; either one is able to carry out the first step, but only one is able to carry out the second step. The reason from this asymmetry is not yet fully determined.

== Cancer == Recently, SCF complexes have become an attractive anti-cancer target because of their upregulation in some human cancers and their biochemically distinct active sites. Though many of the aforementioned FBPs have been implicated in cancer, cytotoxicity has been a limiting factor of drug development. Skp2-targeting anti-sense oligonucleotides and siRNAs are in the drug development pipeline. Preliminary studies have shown that Skp2 downregulation can inhibit the growth of melanomas, lung cancer cells, oral cancer cells, and glioblastoma cells. βTRCP-targeting siRNAs have been shown to sensitize breast cancer cells and cervical cancer cells to existing chemotherapies.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 chemically?

It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.

Does it occur naturally in the body?

The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.

Is it an approved drug?

No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.

How is purity usually measured?

The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.

Network